Sugi Predict

Sugi Predict / Compounds / SCHEMBL2115690

SCHEMBL2115690

SCHEMBL2115690

COC(=O)c1cnc2[nH]ccc2c1Cl

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 6/20 0.55
▸ PRKCI P41743 1/20 0.55
▸ NUDT1 P36639 1/20 0.46
▸ MAP2K1 Q02750 1/20 0.46
▸ TTBK1 Q5TCY1 1/20 0.45
▸ TTBK2 Q6IQ55 1/20 0.45
▸ JAK1 P23458 5/20 0.43
▸ JAK3 P52333 5/20 0.43
▸ CDK8 P49336 1/20 0.42
▸ MGLL Q99685 2/20 0.42
▸ NR4A2 P43354 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30985188 1.00 AXL (0.55) AXLPRKCINUDT1MAP2K1TTBK1
SCHEMBL20956198 0.86 AXL (0.50) AXLPRKCINUDT1JAK1JAK3
SCHEMBL566667 0.86 NUDT1 (0.65) AXLPRKCINUDT1JAK1JAK3
SCHEMBL29477133 0.86 NUDT1 (0.65) AXLPRKCINUDT1JAK1JAK3
SCHEMBL30823440 0.86 AXL (0.50) AXLPRKCINUDT1MAP2K1JAK1
SCHEMBL20956169 0.86 AXL (0.50) AXLPRKCINUDT1MAP2K1JAK1
SCHEMBL31120987 0.85 JAK3 (0.50) AXLPRKCINUDT1JAK1JAK3
SCHEMBL20956013 0.85 JAK3 (0.50) AXLPRKCINUDT1JAK1JAK3
Hydrochloric Acid SCHEMBL29477135 0.85 NUDT1 (0.64) AXLPRKCINUDT1JAK1JAK3
Hydrochloric Acid SCHEMBL29234028 0.85 NUDT1 (0.64) AXLPRKCINUDT1JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300948-A1 Heterocyclic Compounds As Kinase Inhibitors INCYTE CORPORATION 2024-09-12 — — US disclosed
US-20240059680-A1 N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS ELANCO TIERGESUNDHEIT AG (CH) 2024-02-22 — — US disclosed
WO-2023116779-A1 DIALKYNE COMPOUND AND USE THEREOF 上海艾力斯医药科技股份有限公司 2023-06-29 — — WO disclosed
WO-2023116779-A1 DIALKYNE COMPOUND AND USE THEREOF 上海艾力斯医药科技股份有限公司 2023-06-29 — — WO disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
EP-4125914-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2023-02-08 — — EP disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 — — CN disclosed
CN-114478528-A Aroyl-substituted tricyclic compound, preparation method and application thereof 劲方医药科技(上海)有限公司 2022-05-13 — — CN disclosed
WO-2021202977-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-10-07 — — WO disclosed
US-9012470-B2 Therapeutic 5,6,5-tricyclic analogs DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-04-21 — — US disclosed
US-9012470-B2 Therapeutic 5,6,5-tricyclic analogs DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-04-21 — — US disclosed
US-9012470-B2 Therapeutic 5,6,5-tricyclic analogs DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-04-21 — — US disclosed
US-20130345192-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2013-12-26 — — US disclosed
EP-2632898-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS Biogen Idec MA Inc. (US) 2013-09-04 — — EP disclosed
EP-2627655-A2 THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS Dart NeuroScience (Cayman) Ltd (KY) 2013-08-21 — — EP disclosed
WO-2012058645-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2012-05-03 — — WO disclosed
US-20120095016-A1 THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS HELICON THERAPEUTICS, INC. (US) 2012-04-19 — — US disclosed
US-20120095016-A1 THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS HELICON THERAPEUTICS, INC. (US) 2012-04-19 — — US disclosed
WO-2012051213-A2 THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS HELICON THERAPEUTICS, INC. (US) 2012-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP AXL 3118/4885PRKCI 4100/4885NUDT1 209/4885
US-20240059680-A1 N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS TNNT2, TNNI3, SIRT5 AXL 3726/4885PRKCI 4503/4885NUDT1 470/4885
US-20120095016-A1 THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS GABRA5, GABRA6, GABRB1 AXL 4156/4885PRKCI 1898/4885NUDT1 4256/4885
US-20240300948-A1 Heterocyclic Compounds As Kinase Inhibitors JAK2, JAK1, JAK3 AXL 422/4885PRKCI 188/4885NUDT1 1692/4885
US-20130345192-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS TEC, ABL1, LCK AXL 25/4885PRKCI 437/4885NUDT1 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.